MAPK信号通路在肝癌发生发展及治疗中的作用

次旦旺久; 林坤; 卢再鸣; 赵相轩; 王晓明

doi:10.3969/j.issn.1001-5256.2016.09.040

MAPK信号通路在肝癌发生发展及治疗中的作用

DOI: 10.3969/j.issn.1001-5256.2016.09.040

中国医科大学附属盛京医院放射科

基金项目:

国家自然科学基金资助项目(81471720);国家自然科学基金面上项目(31371425)；辽宁省自然科学基金(2013023056)；盛京自由研究者基金(200802)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2134
- HTML全文浏览量: 61
- PDF下载量: 491
- 被引次数: 0
出版历程
- 出版日期: 2016-09-20

The role of MAPK signaling pathway in development/progression and treatment of liver cancer

Department of Radiology, Shengjing Hospital of China Medical University

Research funding:

摘要

摘要:
丝裂原活化蛋白激酶(MAPK)信号通路的异常活化与肝癌的发生、发展、转移密切相关。介绍了MAPK通路蛋白在肝癌中的表达及其在肝癌增殖、分化、转移中的作用,阐述了MAPK信号通路在肝癌治疗及预后评价中的价值。认为MAPK信号通路在肝癌的发生发展及治疗中发挥非常重要的作用,是肝癌治疗及预后评价的潜在分子靶点。
- 肝肿瘤 /
- 丝裂原激活蛋白激酶类 /
- MAP激酶信号系统 /
- 综述
Abstract:
Abnormal activation of the mitogen- activated protein kinase( MAPK) signaling pathway is closely associated with the development,progression,and metastasis of liver cancer. This article introduces the expression of MAPK proteins in liver cancer and its role in the proliferation,differentiation,and metastasis of liver cancer,and elaborates on the value of the MAPK signaling pathway in the treatment and prognostic evaluation of liver cancer. It is pointed out that the MAPK signaling pathway plays an important role in the development/progression and treatment of liver cancer and is a potential molecular target for the treatment and prognostic evaluation of liver cancer.
- liver neoplasms /
- mitogen-activated protein kinases /
- MAP kinase signaling system /
- review

HTML全文

参考文献(41)

[1]MUNSHI A,RAMESH R.Mitogen-activated protein kinases and their role in radiation response[J].Genes Cancer,2013,4(9-10):401-408.

[2]LI JF,DENG YD,ZHANG LT,et al.The role of Ras/ERK signal transduction pathway in the occurrence and development of hepatic fibrosis[J].J Clin Hepatol,2011,27(3):325-327.(in Chinese)李俊峰,邓永东,张立婷,等.Ras/ERK信号转导通路在肝纤维化发生发展中的作用[J].临床肝胆病杂志,2011,27(3):325-327.

[3]DELIRE B,STARKEL P.The Ras/MAPK pathway and hepatocarcinoma:pathogenesis and therapeutic implications[J].Eur J Clin Invest,2015,45(6):609-623.

[4]HAN T,XIANG D M,SUN W,et al.PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients[J].J hepatol,2015,63(3):651-660.

[5]BERASAIN C,NICOU A,GARCIA-IRIGOYEN O,et al.Epidermal growth factor receptor signaling in hepatocellular carcinoma:inflammatory activation and new intracellular regulatory mechanism[J].Dig Dis,2012,30(5):524-531.

[6]YANG L,ZHAO LY,LIU YC,et al.CB1 and ERK gene expression in liver tissue of rats with experimental hepatic fibrosis[J].J Clin Hepatol,2012,28(9):681-684.(in Chinese)杨莉,赵连英,刘彦超,等.大麻素受体1和细胞外信号调节激酶在肝纤维化小鼠肝组织中的表达及意义[J].临床肝胆病杂志,2012,28(9):681-684.

[7]WANG HY,YANG SL,LIANG HF,et al.HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Aktpathways[J].Int J Mol Sci,2014,15(3):3507-3518.

[8]YE H,ZHANG C,WANG BJ,et al.Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice[J].Oncogene,2014,33(43):5133-5138.

[9]NAKAMURA H,AOKI H,HINO O,et al.HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt[J].Hepatol Res,2011,41(5):455-462.

[10]XIE B,XING R,CHEN P,et al.Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference[J].J Surg Res,2010,162(2):231-238.

[11]ZHOU P,HUANG G,ZHAO Y,et al.MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells[J].Cell Signal,2014,26(6):1347-1354.

[12]KOUL KH,PAL M,KOUL S,et al.Role of p38 MAP kinase signal transduction in solid tumors[J].Genes Cancer,2013,4(9-10):342-359.

[13]ESCOS A,RISCO A,ALSINA-BEAUCHAMP D,et al.p38gamma and p38delta mitogen activated protein kinases(MAPKs),new stars in the MAPK galaxy[J].Front Cell Dev Biol,2016,4:31-38.

[14]CHEN KC,CHANG LS.Notexin upregulates Fas and Fas L protein expression of human neuroblastoma SK-N-SH cells through p38MAPK/ATF-2 and JNK/c-Jun pathways[J].Toxicon,2010,55(4):754-761.

[15]AMAKO Y,IGLOI Z,MANKOURI J,et al.Hepatitis C virus NS5A inhibits mixed lineage kinase3 to block apoptosis[J].J Biol Chem,2013,288(34):24753-24763.

[16]SONG MK,PARK YK,RYU JC.Polycyclic aromatic hydrocarbon(PAH)-mediated upregulation of hepatic microRNA-181 family promotes cancer cellmigration by targeting MAPK phosphatase-5,regulating the activation of p38 MAPK[J].Toxicol Appl Pharmacol,2013,273(1):130-139.

[17]YIN J,WANG L,ZHU JM,et al.Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway[J].Oncotarget,2016,7(16):21939-21951.

[18]YARZA R,VELA S,SOLAS M,et al.c-Jun N-terminal Kinase(JNK)Signaling as a therapeutic target for Alzheimer's disease[J].Front pharmacol,2016,6:321.

[19]JIANGX,KANDA T,WU S,et al.Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity[J].World J Gastroenterol,2014,20(23):7197-7206.

[20]KIM S,ISHIDA H,YAMANE D,et al.Contrastin roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus:MKNK1facilitates cell entry[J].J Virol,2013,87(8):4214-4224.

[21]ZHANG YH,WANG SQ,SUN CR,et al.Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro[J].Med Oncol,2011,28(4):966-972.

[22]NI Z,WANG B,DAI X,et al.HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway[J].Free Radic Biol Med,2014,70:194-203.

[23]KOMODA F,SHINO Y,HIRNO T,et al.MEKK1 induces c-Jun complexes that act as negative regulators for cell survival and proliferation of HCC cells[J].Int J Oncol,2002,21(3):553-559.

[24]ZHONG C,LI HD,LIU DY,et al.Clinical study of hepatectomy combined with jianpi huayu therapy for hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2014,15(14):5951-5957.

[25]ZHANG Z,ZHOU X,SHEN H,et al.Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma:evidence from an in vitro study[J].BMC Med,2009,24(7):41-53.

[26]GOPALAN B,NARAYANAN K,KE Z,et al.Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma[J].Biomaterials,2014,35(26):7479-7487.

[27]ZHANG Z,MIAO L,LV C,et al.Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells[J].Cell Death Dis,2013,4(6):e657-e679.

[28]ZHANG J,LAN SJ,LIU QR,et al.Neuroglobin,a novel intracellular hexa-coordinated globin,functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk[J].Mol Pharmacol,2013,83(5):1109-1119.

[29]PUSHPAVALLIS S,RAMAIAH MJ,SRINIVAS CH,et al.Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53,PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1[J].Cancer Cell Int,2011,11(1):36-39.

[30]LIU J,WEI X,WU Y,et al.Giganteaside D induces ROS-mediated apoptosis in human hepatocellular carcinoma cells through the MAPK pathway[J].Cellular oncology(Dordrecht),2016.[Epub ahead of print]

[31]ZHU H,CHEN XP,LUO SF,et al.The role of extracellular signalregulated kinase pathway in multidrug resistance of hepatocellular carcinoma[J].Chin J Surg,2007,45(13):917-920.(in Chinese)朱虹,陈孝平,罗顺峰,等.ERK/MAPK通路参与肝癌产生多药耐药的胞内信号传导[J].中华外科杂志,2007,45(13):917-920.

[32]XI Q,GAO N,YANG Y,et al.Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-ACh E pathway in apoptotic hepatocellular carcinoma cells[J].Int J Biochem Cell Biol,2015,68(11):21-32.

[33]HUANG G,TANG B,TANG K,et al.Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway[J].Oncol Rep,2014,31(5):2377-2384.

[34]LIU J,WEN X,LIU B,et al.Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP2 and MMP9[J].Mol Med Reps,2016,13(3):2401-2408.

[35]LIAO YJ,BAI HY,LI ZH,et al.Longikaurin A,a natural ent-kaurane,induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells[J].Cell Death Dis,2014,5(3):e1137.

[36]TAN J,LAI Z,LIU L,et al.ONTD induces apoptosis of human hepatoma Bel-7402 cells via a MAPK-dependent mitochondrial pathway and the depletion of intracellular glutathione[J].Int J Biochem Cell Biol,2013,45(11):2632-2642.

[37]YAN F,WANG XM,LIU ZC,et al.JNK1,JNK2,and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells[J].Hepatobiliary Pancreat Dis Int,2010,9(3):287-295.

[38]HAGIWARA S,KUDO M,NAGAI T,et al.Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma[J].Br J Cancer,2012,106(12):1997-2003.

[39]CHEN L,SHI Y,JIANG CY,et al.Expression and prognostic role of pan-Ras,Raf-1,p MEK1 and p ERK1/2 in patients with hepatocellular carcinoma[J].Eur J Surg Oncol,2011,37(6):513-520.

[40]WANG SN,LEE KT,TSAI CJ,et al.Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma[J].Eur J Clin Invest,2012,42(12):1295-1301.

[41]HAGIWARA S,KUDO M,CHUNG H,et al.Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma[J].Hepatol Res,2012,42(4):394-400.

施引文献

资源附件(0)

访问统计